Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review.

ABSTRACT: Sickle cell disease (SCD) had first been mentioned in the literature a century ago. Advancement in the molecular basis of the pathophysiology of the disease opens the door for various therapeutic options. Though life-extending treatments are available for treating patients with SCD, allogeneic hematopoietic stem cell transplantation (HSCT) is the only option as of yet. A major obstacle before HSCT to cure patients with SCD is the availability of donors. Matched sibling donors are available only for a small percentage of patients. To expand the donor pool, different contrasting approaches of allogeneic HSCT like T-cell replete and deplete have been tested. None of those tested approaches have been without the risk of GvHD and graft rejection. Other limitations such as transplantation-relate

SUBMITTER: Bhalla N 

PROVIDER: S-EPMC9995916 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature